Abstract Tumor immunotherapy is currently at the cusp of becoming an important aspect of comprehensive cancer treatment in the clinic. However, the need for improved adjuvants to augment immune responses against tumor antigens is always present. In this paper, we characterize the Listeria monocytogenes-derived actin-nucleating protein, ActA, as a novel adjuvant for use in tumor immunotherapy. ActA is a virulence factor that is expressed on the cell surface of L. monocytogenes and facilitates the production of actin tails that propel Listeria throughout the cytosol of an infected host cell. It is believed that this ActA-dependent cytosolic motility allows Listeria to evade adaptive host cell defenses and facilitates its invasion into a proximal uninfected host cell. However, there is evidence that ActA fused to a tumor antigen and delivered by L. monocytogenes can perform a beneWcial function in tumor immunotherapy as an adjuvant. Our investigation of this adjuvant activity demonstrates that ActA, either fused to or administered as a mixture with a tumor antigen, can augment anti-tumor immune responses, break immune tolerance and facilitate tumor eradication, which suggests that ActA is not only an eVective adjuvant in tumor immunotherapy but can also be applied in a number of therapeutic settings.
Introduction
It has been more than a century since the Wrst reports by Dr. William Coley on the utility of bacteria and bacterial products in the treatment of cancer [1, 2] . While the initial work using Streptococcus pyogenes to treat patients' malignancies met with some success, the introduction of radiation therapy marginalized the use of bacteria in cancer treatment [2] . Nevertheless, the utility of bacteria in cancer treatment persisted as evidenced by the use of an attenuated mycobacterium, Bacillus Calmette-Guerin (BCG), as a frontline treatment in bladder cancer [3] . Interestingly, the mechanism of the therapeutic action of BCG is believed to be due to non-speciWc stimulation of the immune system and not due to direct killing of the cancer cells by the bacterium [4] .
Like most pathogens, bacteria stimulate both a strong antigen-speciWc and non-speciWc immune response. While BCG treatment demonstrates the utility of the non-speciWc immune response, many are now harnessing the strong speciWc adaptive immune response induced by a bacterial infection to Wght cancer [5] . There is now growing evidence that recombinant bacteria engineered to express tumorspeciWc antigens are able to stimulate a speciWc anti-tumor adaptive immune response that culminates in tumor destruction [5, 6] . SpeciWcally, attenuated recombinant Listeria monocytogenes (Lm) has proven to be a uniquely adept vaccine vector for stimulation of a strong cytotoxic T lymphocyte (CTL) response and establishment of longterm central memory T cells against speciWc tumor antigens [7, 8] .
While Lm engineered to produce tumor antigens does lead to a speciWc CTL response, anti-tumor eYcacy is greatly augmented by fusing the tumor antigen of interest to the endogenous Lm virulence factor Listeriolysin O (LLO) [7, 8] . LLO is an endogenous pore-forming toxin of Lm that is a well-characterized adjuvant when fused to a tumor antigen and secreted by recombinant Lm [9, 10] . In some instances, the fusion of adjuvant proteins to tumor antigens is believed to facilitate their ubiquitin-mediated degradation and processing for eventual presentation on MHC Class I molecules [11, 12] . Since LLO is an N-end rule-regulated protein and degraded by the ubiquitin-proteasome system, this appears to be a likely mechanism of adjuvancy [12, 13] . Interestingly, it is also reported that delivery of LLO, unfused to a tumor antigen, can also augment an adaptive immune response to the tumor antigen [10] . While this mechanism of adjuvancy is uncharacterized as of yet, there is evidence that LLO can induce signaling that leads to chromatin remodeling and cytokine production independent of its pore-forming ability [14, 15] . This evidence suggests that LLO may be acting as a pathogen-associated molecular pattern (PAMP) much like a number of other adjuvants used in tumor immunotherapy [16] .
We recently found that fusion of another Lm virulence factor, ActA, to a tumor antigen and secreted by a recombinant Lm can also facilitate an augmented anti-tumor immune response [17, 18] . The normal role of ActA in the life cycle of Lm is to function as an actin-nucleating protein, such as WASP [19, 20] . On entering the host cell cytosol, Lm produces and secretes ActA, which induces rapid polymerization of Wlamentous actin through interaction with the Arp2/3 complex [21] . This action allows Lm to propel itself through the host cell cytoplasm to avoid host cell defenses and allow transit to neighboring cells [22] . Interestingly, the host cell rapidly degrades ActA through the ubiqutin-proteasome system in an N-end rule-dependent manner, much like LLO [23] . When ActA is produced and secreted by Lm as a fusion protein, along with a tumor antigen, it demonstrates a similar proWle of adjuvancy as LLO fusion [17, 18] . In studies by Sewell et al. [17] administration of a recombinant Lm that secretes a fusion protein of ActA and HPV 16 E7 leads to regression of tumors expressing E7. Additional work by Souders et al. [18] , demonstrates that this vaccine, Lm-ActAE7, can even lead to strong anti-tumor responses in an E7-tolerized host. The mechanism of adjuvancy by ActA and whether it depends on fusion to the tumor antigen and secretion speciWcally by Lm has, as of yet, not been characterized.
In this study, we characterize the properties of adjuvancy by ActA in tumor immunotherapy. We employ puriWed ActA protein along with the tumor antigen HPV-16 E7 to determine if this is suYcient to provide an eVective antitumor immune response. In addition, we demonstrate that ActA does not need to be covalently conjugated to the tumor antigen for its adjuvancy. We believe that these studies provide insight into the mechanism and eYcacy of ActA as an adjuvant and highlight an additional tool for clinicians to utilize in tumor immunotherapy.
Methods

Mice
C57BL/6 mice, 6-8 weeks old, were purchased from Charles River Laboratories (Wilmington, MA, USA). The HPV16 E6/E7 transgenic mouse on the C57BL/6 background was bred and utilized for tolerance studies and is described elsewhere [18, 24] .
Cell lines
The C57BL/6 syngeneic TC-1 tumor cell line has been immortalized with HPV-16 E6 and E7 and transformed with the H-ras oncogene [25] . TC-1 tumor cells express low levels of E6 and E7 and are highly tumorigenic. TC-1 cells were grown in RPMI 1640 medium, 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 100 mM non-essential amino acids, 1 mM sodium pyruvate, 50 mM 2-ME at 37°C with 7% CO 2 . The J774A.1 immortalized murine macrophage-like cell line was purchased from ATCC and cultured as recommended by the supplier.
Construction and puriWcation of protein vaccines
The gene encoding for ActA (amino acid 25-421) protein was ampliWed using chromosomal material from L. monocytogenes, strain 10403S, using PCR primers: Adv347 (5Ј-TATCGGATCCGCGACAGATAGCGAAGATTCT-3Ј) and Adv102 (5Ј-CGTGCTCGAGAGCTAGGCGATC AATTTCTTC-3Ј). ActA E7 was constructed by fusing ActA to HPV16 E7 in the open reading frame using oligos Adv58 (5Ј-GAAGAAGAAATTGATCGCCTAGCTCT CGAGCATGGAGATACACCTACATTGCATG-3Ј), Adv 59 (5Ј-CATGCAATGTAGGTGTATCTCCATGCTCGA GAGCTAGGCGATCAATTTCTTCTTC-3Ј), Adv347 and Adv125 (5Ј-GTGCTCGAGTGGTTTCTGAGAACAGAT GG-3) by the gene-SOEing PCR method. Both ActA and ActAE7 were cloned into pET30a in the open reading frame with the N-and C-terminal His tags at BamH1 and XhoI sites, respectively. The sequences of the target genes in these plasmids, pAdv 155.2 (ActAE7/pET30a) and 157.1 (ActA/pET30a), were conWrmed by DNA sequencing (Genewiz, PlainWeld, NJ, USA). BL21-DE3 E. coli strain (Invitrogen) was transformed with each ActA plasmid. The 123 E. coli strain expressing HPV16 E7 was obtained as a gift from Dr. Drew Pardoll, Johns Hopkins University. BrieXy, the HPV16 E7 ORF was cloned into pOE30 (Qiagen) and placed in the M15pREP4 Escherichia coli (E. coli) strain (Qiagen). The E7 synthesized in this strain has a histidine motif at the amino terminus to allow puriWcation over an Ni-NTA column. Proteins were puriWed using an Ni-NTA column (Qiagen) according the manufacturer's instructions. The purity of the proteins was veriWed by separating the proteins by SDS-PAGE followed by Coomassie staining. Endotoxins were removed from the puriWed protein preparations with the Norgen Proteospin Endotoxin Removal Maxi kit as per manufacturer's instructions (Norgen Biotek Corporation). Endotoxin removal was conWrmed by Western blotting with anti-LPS core antibody (HyCult Biotechnology).
Phagocytosis assay
The protocol for the Vybrant Phagocytosis Assay Kit (Invitrogen) was followed according to the manufacturer instructions. BrieXy, the J774A.1 macrophage-like cell line was cultured for 4 days and then plated in a 96-well plate at 10 5 cells/well. The cells were then left untreated (positive control) or coincubated with the indicated amounts of puriWed ActA protein in a volume of 150 L of media (DMEM with 10% FBS for 4 h). Additionally, as a negative control, some wells were left cell-free and Wlled only with 150 L of media. After 4 h of incubation, Xuorescein-labeled E. coli (K-12 strain) BioParticles were added to the wells and phagocytic uptake was allowed to proceed for 2 h. Trypan blue was then added to each well to quench the Xuorescence of any extracellular non-phagocytosed bioparticles. Phagocytic uptake was then measured with a Xuorescent microplate reader by absorbance at O.D. 535 nm.
Tumor load study TC-1 tumor cells (2 £ 10 5 ) were injected subcutaneously (s.c.) into the Xanks of either wild-type C57BL/6 mice or C57BL/6 mice transgenic for HPV-16, E6 and E7 (8 mice/ group). After allowing the tumors to establish for 7 days at which time they were palpable and roughly 5 mm in diameter, protein vaccines were administered s.c. at equimolar amounts (3.3 mol) as follows: 50 g of E7, 200 g of ActA and 250 g of ActA genetically fused to E7 (ActAE7), or 50 g of E7 mixed with 200 g of ActA (ActA + E7) per mouse. Mice were immunized again on day 14 and tumor growth was measured every 3 days with calipers. Tumors with a volume of less than 9 mm 3 could not be measured and the mice were classiWed as tumor free. The mice were killed when the tumor volume reached >4,000 mm Metastatic tumor study TC-1 tumor cells (2 £ 10 5 ) were injected intravenously into the tail vein of C57BL/6 mice (5-6 mice/group). On days 5 and 12 post-injection, protein vaccines were administered s.c. at equimolar amounts (3.3 mol) as described above. The mice were then killed on day 30 and the lungs isolated and perfused with PBS. Lung surface metastatic nodules per lung were then counted with a Nikon SMZ1B Zoom Stereomicroscope attached to a Fostec 8375 Illuminator and Ringlight.
Depletion experiments
CD8
+ cells were depleted in TC-1 tumor-bearing mice by injecting the mice with 0.5 mg of anti-CD8 antibody (clone 2.43) on days 6, 7, 8, 10, 12 and 14 post-tumor challenge. As a control, a group of mice were treated under the same conditions with an isotype matched, control antibody speciWc for beta-galactosidase. The concurrent tumor load study was adhered to as described in "Tumor load study" in this "Methods" section.
ELISpot analysis
The 96-well Wltration plates (Millipore, Bedford, MA, USA) were coated with 15 g/ml rat anti-mouse IFN-antibody (clone AN18, MABTECH, Mariemont, OH, USA) in 100 l of PBS. After overnight incubation at 4°C, the wells were washed and blocked with culture medium containing 10% fetal bovine serum. Splenocytes from each experimental group (1 £ 10 5 or 2 £ 10 4 per well) were added to the wells along with E7 protein (5 g/ml) or E7-speciWc H-2Db CTL epitope, RAHYNIVTF (5 g/ml) [26] plus IL-2 (5 U/ ml). The cells were incubated at 37°C for 24 h. The plate was washed followed by incubation with 1 g/ml biotinylated IFN-antibody (clone R4-6A2, MABTECH, Mariemont, OH, USA) in 100 l of PBS at 4°C overnight. After washing, 1:100 streptavidin-horseradish peroxidase in 100 l of PBS was added and incubated for 1 h at room temperature. Spots were developed by adding 100 l of substrate after washing and incubated at room temperature for 15 min. Color development was stopped by washing extensively in tap water and spot-forming cells (SFC) were counted on an ELISpot reader. The ability of each ActA vaccination to enhance IFN-secretion responses was statistically compared against the E7 vaccine alone as described below.
Detection of E7-speciWc tumor-inWltrating lymphocytes C57BL/6 mice were implanted with TC-1 tumors and immunized s.c. with E7, ActA, ActA + E7 or ActAE7 and boosted 7 days later as described above. Tumors were harvested 9 days after boosting and manually dissociated into a single-cell suspension. The tumor cell suspension was then Ficoll puriWed to remove dead cells and cellular debris by excluding the low-density fraction after centrifugation. The remaining tumor cells were then subjected to threecolor Xow cytometry for CD8 (53-6.7, FITC conjugated), CD62 ligand (CD62L; MEL-14, APC conjugated) and E7 H-2Db tetramer-PE conjugated (RAHYNIVTF) using a FACSCalibur Xow cytometer with CellQuest software (Becton-Dickinson, Mountain View, CA, USA). Tetramers were provided by the National Institute of Allergy and Infectious Diseases Tetramer Core Facility and used at a 1/ 200 dilution. Results from three separate experiments were combined and analyzed as described above to compare the ability of each ActA vaccination to induce tetramer + , CD8 + , CD62L
¡ and E7-speciWc tumor-inWltrating lymphocytes with E7 vaccination alone.
Statistical analyses
One-tailed student's t tests were performed comparing E7 vaccination to either ActA + E7 or ActAE7 vaccination for all data except for Fig. 1c where the positive control was compared to ActA (100, 10, and 1 ng) treatment using GraphPad Prism version 4.0a for Macintosh (San Diego, CA, USA, http://www.graphpad.com). SigniWcant p values for all comparisons are depicted in Wgures as follows: *p < 0.05, **p < 0.01 and ***p < 0.001. Non-signiWcant p values are depicted as ns.
Results
Characterization of ActA vaccines
To determine the adjuvant properties of ActA, the pET expression system was utilized for the production and puriWcation of E7, ActA and ActAE7 (Fig. 1) . Proper puriWcation of each protein was determined by SDS-PAGE analysis followed by Coomassie staining (Fig. 1a) . While all preparations appeared to be very pure, the ActAE7 preparation had a faint band corresponding to non-fused ActA. We had previously observed a similar phenomenon where similar fusion proteins partially dissociated on secretion by Listeria (data not shown).
Since the nature of the experiments necessitated that most endotoxins were eliminated, puriWed proteins were detoxiWed at least twice with Norgen ProteoSpin columns (Norgen Biotek Corporation). DetoxiWed proteins were Fig. 1 Characterization of ActA vaccines. a PuriWed proteins used for this study were subjected to SDS-PAGE analysis on a discontinuous polyacrylamide gel and then subsequently stained with Coomassie stain. A graphical depiction of each protein utilized in this study is depicted alongside the respective band. b PuriWed proteins were subjected to SDS-PAGE analysis before and after endotoxin removal along with LPS as a positive control. A Western blot with -LPS antibody was performed to demonstrate proper elimination of endotoxin from puriWed proteins. c PuriWed and detoxiWed ActA protein was incubated with the murine macrophage-like cell line, J774, and phagocytosis was assayed with the Vybrant Phagocytosis Assay Kit (Invitrogen). Phagocytosis of GFP-labeled heat-killed E. coli was measured by detection of emission at 535 nm then subjected to SDS-PAGE analysis and Western blotting with anti-LPS core antibody. As shown, in Fig. 1b , LPS is detected in both ActA preparations prior to detoxiWcation, but is completely undetectable after detoxiWcation.
Listeria-secreted ActA is highly eYcient at nucleating Wlamentous actin in the cytosol of infected host cells; it was also important to determine if our puriWed ActA protein would aVect an important actin-dependent cellular process, phagocytosis. Phagocytosis is the process in which foreign antigens are engulfed and processed by antigen-presenting cells and its impairment would likely inhibit uptake of a target antigen and, subsequently, anti-tumor immune responses. However, as seen in Fig. 1c , incubation of puriWed ActA protein along with the J774A.1 murine macrophage-like cell line did not signiWcantly aVect the ability of the cells to phagocytose Xuorescein-labeled bioparticles in comparison to untreated cells.
ActA enhances anti-tumor eYcacy against a target antigen
The eYcacy of ActA as an adjuvant was assayed against a widely used tumor model for HPV16-associated cancer, TC-1, which is a transformed lung epithelial cell line immortalized by HPV16 E6 and E7, followed by transformation with the H-ras oncogene. The constitutive expression of HPV16 E7 by TC-1 allows for eVective and targeted tumor immunotherapy in both a therapeutic and preventive model of HPV-associated tumors. To assay for the ability of ActA to enhance anti-tumor immune responses, TC-1 tumor cells were implanted s.c. into the hind Xank, and puriWed ActA and E7 proteins were administered on day 7 post-implantation either alone, mixed or genetically fused. Vaccinated mice were then boosted on day 14 post-implantation and tumor volume measured throughout. Shortly after vaccination with either the ActA + E7 mix or the ActAE7 fusion protein, reduced growth or regression of tumors was observed. However, vaccination with either E7 protein or ActA protein alone had little eVect on tumor growth. Additionally, over half of the mice in the regimens that included both ActA and E7 were tumor free by the completion of the experiment, whereas no mice treated with E7 alone and only one mouse treated with ActA alone were tumor free. In addition, the mice tolerated the vaccines well with no observable adverse symptoms. To assess whether ActA + E7 regimens lead to the creation of central memory T cells and long-term immunity, tumor-free mice from the previous experiment were re-challenged 2 months after initial tumor implantation with TC-1 tumor cells and tumor outgrowth was monitored. All TC-1 rechallenged mice remained tumor free, while unvaccinated and tumor-naïve mice, implanted with the same TC-1 cells, grew tumors as expected with the same TC-1 cells (data not shown), suggesting that ActA can stimulate an eVective long-lasting immune response to a targeted antigen. In addition to augmenting therapeutic responses against a primary tumor, ActA is also an eVective adjuvant in a model of metastatic disease. After intravenous tail vein injection of TC-1 cells, mice were subsequently vaccinated twice and lungs removed on day 30 post-implantation. Examination of the lungs for TC-1 revealed that vaccination with ActA + E7 and ActAE7 signiWcantly reduced (p = 0.001 and p = 0.0002, respectively) the number of surface lung metastases (1.6 § 0.5 metastases/lung and 0.6 § 0.2 metastases/lung, respectively) detectable at day 30 in comparison to vaccination with E7 alone (7.4 § 1 metastases/lung) (Fig. 2c) .
ActA facilitates a CD8
+ cell-dependent anti-tumor immune response Evidence suggests that the most eVective anti-tumor immune responses are dependent upon a strong CD8 + T-cell response against the tumor [as reviewed in 27] . To determine the importance of the CD8 + T-cell response after ActA + E7 vaccination, mice were implanted with TC-1 tumor cells and depleted of CD8 + cells. Subsequently, depleted and non-depleted control mice were vaccinated with either of the ActA + E7 vaccine regimens. While vaccination with ActA protein along with E7 protein led to complete tumor regression in 62.5% of mice 42 days after tumor implantation, depletion of CD8 + cells resulted in rapid tumor outgrowth in all mice. Similar results were observed after vaccination with ActA fused to E7, wherein, CD8 + cell depletion resulted in the rapid outgrowth of tumors (Fig. 3) .
ActA vaccines augment E7-speciWc IFN-production by CD8 + T cells in spleens and tumors
Previous work demonstrated that a Listeria-based vaccine secreting ActA fused to E7 can lead to elevated levels of E7-speciWc CTLs in the spleen and tumor [17, 18] . As seen in Fig. 4a and b, the ActA + E7 and ActAE7 fusion protein vaccinations both resulted in an increased percentage of E7-speciWc CTLs in the spleen. In addition, as seen in Fig. 5b , the mean percentage of tumor inWltrating activated E7-speciWc CD8 + T cells was highly elevated in the tumors of ActAE7 and ActA plus E7 vaccinated mice in comparison to control vaccinated mice. While the increased presence of E7-speciWc CD8 + T cells was a good prognosis for vaccine eYcacy in previous studies [8] , we wanted to examine the functionality of these antigen (Fig. 4c) . As expected, depletion of CD4 + splenocytes has little eVect on E7-peptide-speciWc IFN-secretion suggesting that this response is mainly due to CD8 + splenocytes. However, vaccination with ActA along with E7, either mixed or genetically fused, resulted in approximately double the amount of E7-speciWc IFN--secreting CD8
+ splenocytes compared to E7 alone. Similar results were observed in the tumors of vaccinated mice (Fig. 5c ).
Overcoming immune tolerance to tumor antigens by ActA Since most tumor antigens are actually self-proteins, the importance of an adjuvant to facilitate the breaking of immune tolerance is paramount [28] . To assay for the ability of ActA to overcome immune tolerance, we utilized the E6/E7 transgenic mouse on the C57BL/6 background along with s.c.-implanted TC-1 tumors. As in the wild-type mouse, vaccination of mice with ActA + E7 and ActAE7 was able to facilitate an eVective therapeutic anti-tumor response against implanted TC-1 tumors in the E6/E7 transgenic mouse. While the E7 vaccination alone reduced tumor growth slightly over the course of the experiment, eVective tumor regression was only observed in the ActA + E7 and ActAE7 vaccinated mice. In fact, the ActA + E7 and ActAE7 vaccine regimens led to complete regression of TC-1 tumors in 62.5% of mice and signiWcant tumor reduction in the rest of the immunized mice. In addition, these therapeutic responses correlated with increased E7-speciWc responses in the spleen. The ActA + E7 and ActAE7 vaccine regimens induced a signiWcant increase in the numbers of E7-speciWc IFN--secreting splenocytes (137 § 2 SFC/2 £ 10 6 cells and 107 § 3.8 SFC/ 2 £ 10 6 cells, respectively) in comparison to E7 vaccination alone (13 § 0.6 SFC/2 £ 10 6 cells) as measured by ELISpot assay. We also observed signiWcantly elevated percentages of activated (CD62L ¡ ) E7-tetramer positive CTLs in the spleens of ActA + E7 and ActAE7 vaccinated mice (5 § 0.9 and 10.7 § 1, respectively) in comparison to E7 vaccinated mice (0.8 § 0.2) (Fig. 6 ).
Discussion
In this paper, we present evidence suggesting that the Listeria-derived virulence factor, ActA, is a novel adjuvant that can facilitate speciWc tumor immunotherapy. Vaccination with ActA along with a tumor-speciWc antigen resulted in increased levels and generation of tumor-speciWc CD8 + T cells. Ultimately, this resulted in the eradication of tumors in a CD8 + T-cell-dependent manner after vaccination with ActA and the tumor-speciWc antigen.
Previously, we have demonstrated that ActA enhances anti-tumor immunogenicity when fused to a tumor-speciWc antigen and secreted by recombinant Lm [17, 18] . We hypothesized that fusion of ActA to the antigen may provide greater immunogenicity through increased antigen presentation. This rationale is based on a report that the ubiquitin-proteasome machinery eYciently processes ActA in an N-end rule-dependent manner [23] . Fusion of a tumor-speciWc antigen to ActA would then likely facilitate its ubiquitin-mediated degradation and presentation of its antigenic CTL peptides on Class I MHC molecules. However, results presented in this paper suggest that though ActA fusion may facilitate increased antigen processing and presentation, it appears to only slightly augment additional anti-tumor eYcacy over the non-fused ActA vaccination regimen. This study demonstrates that ActA does not need to be secreted by Listeria or fused to the tumor-speciWc antigen to gain the beneWts of its adjuvant properties. Similar results were reported previously with another Listeriaderived virulence factor, LLO, in a tumor immunotherapy setting [8] . One likely mechanism through which ActA could be facilitating anti-tumor immune responses is by acting as a PAMP like other bacterial adjuvants such as CPG and LPS [16] . PAMPs are recognized by speciWc pathogen recognition receptors (PRRs) that activate an immunostimulatory cascade leading to the release of proinXammatory cytokines such as TNF-and IL-12 [29] [30] [31] [32] . These critically important cytokines facilitate the maturation of antigen-presenting cells and the activation of antigen-speciWc CTLs [33] . PAMPs are used widely in tumor immunotherapy to facilitate strong CD8-mediated antitumor immune responses similar to those induced by ActA vaccination [16] . We are currently investigating whether ActA has PAMP properties.
While there is no evidence to suggest that actin-nucleation factors alone and/or added extracellularly can facilitate immune responses, we cannot completely eliminate that this function of ActA plays a role in our vaccines. The ActA utilized in our vaccines contains all three of the reported actin-nucleation sites [34] . In addition, actin remodeling plays a critical role in dendritic cell phagocytosis and T-cell activation during an immune response [35, 36] . While we demonstrate no adverse or enhanced phagocytosis by a macrophage-like cell line after ActA treatment, further investigation is required to determine the importance of actin nucleation by ActA as a mechanism for adjuvancy in tumor immunotherapy.
With the data presented in this paper, we have characterized a novel adjuvant for tumor immunotherapy, ActA. While the molecular mechanisms governing its adjuvant activity require further investigation, its ability to stimulate an eVective CD8-mediated anti-tumor immune response capable of overcoming tolerance make ActA an attractive option for future therapies. In addition, the ability of ActA to function as an adjuvant without fusion demonstrates versatility in its ability to be rapidly applied in the treatment of various malignancies in the clinic. 
